Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.09%
- Poor long term growth as Operating profit has grown by an annual rate of -16.96%
Flat results in Dec 25
Stock is technically in a Mildly Bearish range
With ROE of 0.5, it has a Very Expensive valuation with a 0.2 Price to Book Value
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
Ganges Securitie for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Compliances-Reg.24(A)-Annual Secretarial Compliance
27-May-2026 | Source : BSEAnnual Secretarial Compliance Report
Board Meeting Intimation for Audited Financial Results For FY 2025 - 26
03-May-2026 | Source : BSEGanges Securities Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 14 2026 inter alia to: a) approve and take on record the Audited Financial Results of the Company for the quarter and financial year ended on March 31 2026; and b) recommend Dividend if any for the financial year ended 31st March 2026 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. This is for your information and records.
Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Apr-2026 | Source : BSECopy of Newspaper Publication
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.01%)
Held by 1 FIIs (0.03%)
Sil Investments Limited (13.38%)
Navjeewan Medical Institute (6.21%)
21.69%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -14.20% vs 1.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is 82.50% vs -40.30% in Dec 2024
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -4.41% vs 19.10% in Sep 2024
Growth in half year ended Sep 2025 is -52.87% vs 35.93% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -7.98% vs 11.81% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -41.05% vs 22.30% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 9.08% vs -15.57% in Mar 2024
YoY Growth in year ended Mar 2025 is 45.40% vs -64.31% in Mar 2024